Tradipitant improves symptoms of motion sickness

The investigational agent tradipitant successfully reduced the incidence of nausea and vomiting associated with motion sickness in a clinical trial. Both the low and high doses were well-tolerated.

“Motion sickness may be evoked due to a sensory processing mismatch between the vestibular, somatosensory, and visual systems,” said Dr Vasilios Polymeropoulos (Vanda Pharmaceuticals, NY, USA) [1]. “Vomiting and nausea are the key symptoms, and motion sickness may occur in up to 30% of the population.”

Tradipitant, a selective inhibitor of human cell membrane NK-1 receptor binding, was assessed in participants with a history of motion sickness (n=316). Participants were randomised 1:1:1 to tradipitant 170 mg, tradipitant 85 mg, or a placebo. The primary outcome was the prevention of vomiting from motion sickness during vehicle travel, as measured by Vomiting Assessment (VA).

The results showed a vomiting incidence of 10.4% in the 170 mg arm, significantly lower than in the placebo arm (37.7%; P<0.0001). Similarly, the 85-mg arm was associated with a lower vomiting incidence than the placebo arm (18.3% vs 37.7%; P=0.0014; see Figure). Furthermore, tradipitant intake resulted in a reduced incidence of severe nausea and vomiting (combined tradipitant arms 13.3% vs 33%; P<0.0001).

Figure: Vomiting incidence with tradipitant and placebo [1]



“Overall, tradipitant was effective in reducing vomiting and preventing nausea in this population, with the higher dose displaying slightly better results than the lower dose,” summarised Dr Polymeropoulos. “Given the prevalence of adverse events associated with other therapies such as dimenhydrinate and scopolamine, the well-tolerated agent tradipitant may be beneficial for many travellers.”

1. 
   
   1. Polymeropoulos V, et al. Motion serifos: tradipitant effective in the prevention of vomiting in motion sickness during sea travel. LB13, UEG Week 2024, 12–15 October, Vienna, Austria.

Copyright ©2024 Medicom Medical Publishers



Posted on 28 November 202428 November 2024